ELMD vs RMD
ELMD: Electromed is a medical technology company that helps patients breathe easier by providing innovative, self-administered High Frequency Chest Wall Oscillation (HFCWO) airway clearance therapy. RMD: ResMed is a leading provider of AI-powered, cloud-connected medical devices and software that revolutionize the management of sleep apnea and chronic respiratory conditions at home.
Side-by-side fundamentals
| Metric | ELMD | RMD | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $27.32 | $246.20 | |
| Market cap | $229M | $35.5B | |
| P/E as of 2026-10-21 | 21.02 | 23.60 | ELMD lower |
| PEG as of 2026-10-21, 3-year EPS CAGR to FY2026 | 0.39 | 1.20 | ELMD lower |
| Net margin FY2026, SEC XBRL | +15.3% | +26.9% | RMD higher |
| Gross margin FY2026, SEC XBRL | +78.5% | +61.1% | ELMD higher |
| Operating margin FY2026, SEC XBRL | +18.8% | +33.4% | RMD higher |
| ROE FY2026, SEC XBRL | +20.9% | +23.1% | RMD higher |
| ROA FY2026, SEC XBRL | +17.1% | +17.0% | ELMD higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.10 | |
| Revenue growth (YoY) FY2026, SEC XBRL | +15.3% | +9.8% | ELMD higher |
| Revenue CAGR (3y) SEC XBRL | +15.4% | +10.2% | ELMD higher |
| Dividend yield as of 2026-09-02 | n/a | +1.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 14 | RMD higher |
| Beta as of 2026-09-03 | 0.81 | 0.58 | |
| 1-year return as of 2026-10-21 close | +10.3% | -8.2% | ELMD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.